Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
August 10, 2021 16:01 ET
|
Altimmune, Inc.
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline ...
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021
August 04, 2021 16:01 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial...
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
June 29, 2021 16:01 ET
|
Altimmune, Inc.
AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteersAltimmune will discontinue further development of AdCOVID and focus its resources on its ongoing...
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
June 16, 2021 07:00 ET
|
Altimmune, Inc.
Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment targetAscending multi-dose regimen well-tolerated without necessity for...
Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference
May 27, 2021 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during...
Altimmune Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™
May 26, 2021 07:00 ET
|
Altimmune, Inc.
Similar Neutralization Titers Observed for Both Ancestraland B.1.351 South African Variant Phase I Clinical Trial of AdCOVID Expected to Report Data in June 2021 GAITHERSBURG, Md., May 26, 2021 ...
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
May 17, 2021 07:00 ET
|
Altimmune, Inc.
Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline GAITHERSBURG, Md., May 17,...
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
May 11, 2021 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial...
Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose
May 10, 2021 07:00 ET
|
Altimmune, Inc.
Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2 Sterilizing Immunity Believed to be Critical for Blocking Viral Transmission ...
Altimmune to Present at Upcoming Scientific Conferences
April 29, 2021 07:00 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...